Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?

Osteoanabolic agents are used as a first line treatment in patients at high fracture risk. The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone mineral density (BMD), and bone strength by activating PTH receptors on osteoblasts. Romosozumab (ROMO), a humanized monoclonal antibody against sclerostin, dramatically but transiently stimulates bone formation and persistently reduces bone resorption. Osteoanabolic agents increase BMD and bone strength while being more effective than antiresorptives in reducing fracture risk in postmenopausal women. However, direct comparisons of the antifracture benefits of osteoanabolic therapies are limited. In a direct comparison of TPTD and ABL, the latter resulted in greater BMD increases at the hip. While no differences in vertebral or non-vertebral fracture risk were observed between the two drugs, ABL led to a greater reduction of major osteoporotic fractures. Adverse event profiles were similar between the two agents except for hypercalcemia, which occurred more often with TPTD. No direct comparisons of fracture risk reduction between ROMO and the PTH1R agonists exist. Individual studies have shown greater increases in BMD and bone strength with ROMO compared with TPTD in treatment-naive women and in women previously treated with bisphosphonates. Some safety aspects, such as a history of tumor precluding the use of PTH1R agonists, and a history of major cardiovascular events precluding the use of ROMO, should also be considered when choosing between these agents. Finally, convenience of administration, reimbursement by national health systems and length of clinical experience may influence patient choice.
Competing Interests: Conflict of interest: Athanasios D. Anastasilakis reports lecture fees from Amgen, Bianex, Eli-Lilly, Galenica, ITF, Unifarma, and UCB; Maria P. Yavropoulou reports lecture fees from Amgen, Galenica and Genesis; Andrea Palermo reports lecture fees from Amgen, Theramex and UCB; Polyzois Makras reports fees for lectures/advisory boards and research grants from Amgen and Galenica and fees for lectures/advisory boards from UCB, Elpen, Bianex, Eli-Lilly, ITF, Unipharma, and Rapharm; Julien Paccou reports honoraria for lectures/advisory boards from Amgen, Besins, CDD, Lilly, UCB, and Theramex; Gaia Tabacco reports lectures fees from Theramex and Abiogen, Anda M. Naciu reports lecture fees from Theramex; Elena Tsourdi reports honoraria for lectures and advisory boards from Amgen, UCB, Ascendis, Kyowa Kirin, and educational grants from Ascendis and UCB. Co-authors Elena Tsourdi is on the editorial board of EJE. She was not involved in the review or editorial process for this paper, on which she is listed as an author.
(© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)